PMID- 36966325 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230328 IS - 1758-5996 (Print) IS - 1758-5996 (Electronic) IS - 1758-5996 (Linking) VI - 15 IP - 1 DP - 2023 Mar 25 TI - Luteolin intake is negatively associated with all-cause and cardiac mortality among patients with type 2 diabetes mellitus. PG - 59 LID - 10.1186/s13098-023-01026-9 [doi] LID - 59 AB - BACKGROUND: Luteolin, a common flavonoid in our daily diet, has potent anti-diabetic effects. However, its prognostic impact on type 2 diabetes mellitus (T2DM) is still uncertain. This study aimed to clarify this association. METHODS: In this prospective cohort study, 2,461 patients with T2DM were included from the National Health and Nutrition Examination Survey. Dietary luteolin intake was estimated by the type and amount of food consumed in a 24-hour dietary recall. All-cause and cardiac mortality were ascertained by National Death Index Mortality data (as of December 31, 2019). The association of luteolin intake with mortality risk was estimated by Cox proportional hazards model. RESULTS: The median (interquartile range) luteolin intake was 0.355 (0.130, 0.835) mg/day. During the follow-up (median, 8.4 years), 561 all-cause deaths (including 136 cardiac deaths) were documented. Per-unit increment of luteolin intake (natural logarithm transformed) was found to reduce all-cause mortality by 7.0% (P = 0.024) and cardiac mortality by 22.6% (P = 0.001) in patients with T2DM. An inverse dose-response association was identified between luteolin intake (range: 0.005-9.870 mg/day) and mortality risk. The consistent result was also shown when stratified by age, gender, race, body mass index, HbA1c level, and T2DM duration. Moreover, luteolin intake increment was also shown to be associated with a lower C-reactive protein level at baseline (beta =-0.332; 95% CI =-0.541, -0.122). CONCLUSION: The current study confirmed that the dietary luteolin intake increment reduced all-cause mortality (especially cardiac mortality) in patients with T2DM, which may be attributed to the anti-inflammatory property of luteolin. CI - (c) 2023. The Author(s). FAU - Zhang, Wenbin AU - Zhang W AD - Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. AD - Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China. FAU - Li, Duanbin AU - Li D AD - Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. AD - Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China. FAU - Shan, Yu AU - Shan Y AD - Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. AD - Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China. FAU - Tao, Yecheng AU - Tao Y AD - Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. AD - Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China. FAU - Chen, Qingqing AU - Chen Q AD - Department of Cardiology, Zhejiang Hospital, Hangzhou, Zhejiang, People's Republic of China. FAU - Hu, Tianli AU - Hu T AD - Department of Cardiology, The Fourth Affiliated Hospital, College of Medicine, Zhejiang University, Yiwu, Zhejiang, People's Republic of China. FAU - Gao, Menghan AU - Gao M AD - College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. FAU - Chen, Zhezhe AU - Chen Z AD - Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. AD - Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China. FAU - Jiang, Hangpan AU - Jiang H AD - Department of Cardiology, The Fourth Affiliated Hospital, College of Medicine, Zhejiang University, Yiwu, Zhejiang, People's Republic of China. FAU - Du, Changqin AU - Du C AD - Department of Cardiology, Zhejiang Hospital, Hangzhou, Zhejiang, People's Republic of China. FAU - Wang, Min AU - Wang M AD - Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. wangminsyf30508@zju.edu.cn. AD - Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China. wangminsyf30508@zju.edu.cn. FAU - Guo, Kai AU - Guo K AD - Department of Cardiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai, 200092, People's Republic of China. guokai@xinhuamed.com.cn. LA - eng GR - 82070408/National Natural Science Foundation of China/ GR - 2021RC014/Medical Health Science and Technology Project of Zhejiang Provincial Health Commission/ GR - 2021ZB172/Traditional Chinese Medicine Science and Technology Project of Zhejiang Province/ PT - Journal Article DEP - 20230325 PL - England TA - Diabetol Metab Syndr JT - Diabetology & metabolic syndrome JID - 101488958 PMC - PMC10039598 OTO - NOTNLM OT - All-cause mortality OT - Cardiac mortality OT - Diabetes OT - Luteolin OT - NHANES COIS- The authors declare that they have no competing interests. EDAT- 2023/03/26 06:00 MHDA- 2023/03/26 06:01 PMCR- 2023/03/25 CRDT- 2023/03/25 23:25 PHST- 2022/09/30 00:00 [received] PHST- 2023/03/11 00:00 [accepted] PHST- 2023/03/25 23:25 [entrez] PHST- 2023/03/26 06:00 [pubmed] PHST- 2023/03/26 06:01 [medline] PHST- 2023/03/25 00:00 [pmc-release] AID - 10.1186/s13098-023-01026-9 [pii] AID - 1026 [pii] AID - 10.1186/s13098-023-01026-9 [doi] PST - epublish SO - Diabetol Metab Syndr. 2023 Mar 25;15(1):59. doi: 10.1186/s13098-023-01026-9.